Anti C5 Complement mAb Placebo
Sponsors
Alexion Pharmaceuticals Inc.
Conditions
Delayed Graft Function after Kidney TransplantationHematopoietic stem cell transplant-associated thrombotic microangiopathyImmunoglobulin A Nephropathy (IgAN)Prevention of cardiac surgery associated acute kidney injury
Phase 3
ARTEMIS: RAvulizumab to PRotect PaTients with Chronic Kidney DisEase (CKD) froM Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI) and Subsequent Major Adverse Kidney Events (MAKE): A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study
Active, not recruitingCTIS2022-501802-36-00
Start: 2023-06-16Target: 270Updated: 2025-07-17
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Ravulizumab in Adult and Adolescent Participants who have Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplant (HSCT)
Active, not recruitingCTIS2023-510107-22-00
Start: 2020-10-27Target: 61Updated: 2025-07-09
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Immunoglobulin A Nephropathy (IgAN)
RecruitingCTIS2023-507851-31-00
Start: 2024-09-23Target: 148Updated: 2025-11-04
A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function after Kidney Transplantation
RecruitingCTIS2024-517568-48-00
Start: 2025-07-21Target: 164Updated: 2025-09-23